Marker Therapeutics (MRKR)

• Market cap: $19.5M
• 1 day: -5.33%
• 5 days: -11.11%
• 1 month: 40.35%
• 3 months: 35.59%
• 6 months: -60.69%
• Year to date: -49.69%
• 1 year: -60.20%
• 5 years: -92.31%
• 10 years: -97.07%
• Sector: Healthcare
• Industry: Biotechnology

About: Marker Therapeutics Inc is a clinical-stage immuno-oncology company specializing in the development and commercialization of novel T cell-based immunotherapies and peptide-based vaccines for the treatment of hematological malignancies and solid tumor indications. The company develops product candidates from its MultiTAA T cell technology, which is based on the selective expansion of non-engineered, tumor-specific T cells that recognize tumor-associated antigens, or TAAs, which are tumor targets, and then kill tumor cells expressing those targets.

Employees: 5

Fund manager confidence

Based on 2025 Q1 regulatory disclosures by fund managers ($100M+ AUM)

67% more repeat investments, than reductions

Existing positions increased: 10 | Existing positions reduced: 6

0% more first-time investments, than exits

New positions opened: 3 | Existing positions closed: 3

3% less funds holding

Funds holding: 33 [Q4 2024] → 32 (-1) [Q1 2025]

3.51% less ownership

Funds ownership: 41.77% [Q4 2024] → 38.26% (-3.51%) [Q1 2025]

90% less capital invested

Capital invested by funds: $49.5M [Q4 2024] → $5.04M (-$44.4M) [Q1 2025]

Research analyst outlook

1 Wall Street Analyst provided 1 year price targets over the past 3 months

• Low target: $12.50 681% upside
• Avg. target: $12.50 681% upside
• High target: $12.50 681% upside

1 analyst rating

• positive: 1 100%
• neutral: 0 0%
• negative: 0 0%

WBB Securities Steve Brozak

681% upside $12.50

Strong Buy Reiterated

1 Apr 2025